GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curasight AS (XSAT:CURAS) » Definitions » Notes Receivable

Curasight AS (XSAT:CURAS) Notes Receivable : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Curasight AS Notes Receivable?

Curasight AS's Notes Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Curasight AS Notes Receivable Historical Data

The historical data trend for Curasight AS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curasight AS Notes Receivable Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Curasight AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Curasight AS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Curasight AS Notes Receivable Related Terms

Thank you for viewing the detailed overview of Curasight AS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Curasight AS Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. The company is focused on exploiting Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor.

Curasight AS Headlines

No Headlines